Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. Medtronic ( MDT) pushed the Health Services industry lower today making it today's featured Health Services laggard. The industry as a whole closed the day down 0.3%. By the end of trading, Medtronic fell 53 cents (-1.1%) to $45.42 on average volume. Throughout the day, 6.3 million shares of Medtronic exchanged hands as compared to its average daily volume of 4.5 million shares. The stock ranged in price between $45.42-$45.96 after having opened the day at $45.80 as compared to the previous trading day's close of $45.95. Other companies within the Health Services industry that declined today were: SunLink Health Systems ( SSY), down 11.8%, Navidea Biopharmaceuticals ( NAVB), down 8.3%, Unilife Corporation ( UNIS), down 8%, and Kips Bay Medical ( KIPS), down 7.3%.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. Medtronic has a market cap of $46.5 billion and is part of the health care sector. The company has a P/E ratio of 14, below the S&P 500 P/E ratio of 17.7. Shares are up 12% year to date as of the close of trading on Thursday. Currently there are eight analysts that rate Medtronic a buy, no analysts rate it a sell, and 10 rate it a hold. TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and attractive valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.